Ischemic changes in the electrocardiogram (ECG), along with metabolic syndrome (MetS) and its components, can be utilized to predict cardiovascular diseases (CVDs). However, the exact association between MetS components and ECG abnormalities is not well established. This study was designed to verify this association.
Methods:
This cross-sectional study was conducted on individuals aged 35–65 years as part of the population-based Mashhad Stroke and Heart Atherosclerotic Disorder (MASHAD) study. Participants were allocated into two groups based on the presence of MetS. ECGs were coded using the Minnesota coding system. The association between each MetS component and every ischemic ECG presentation was analyzed separately.
Results:
Among the 9,035 available ECG data, the overall prevalence of ischemic ECG presentations was significantly higher in those with MetS than in those without (P < 0.05), except for minor ischemia (P = 0.787). Multiple logistic regression analysis showed that MetS was independently associated with major ischemia presentation in ECG (OR = 1.254, 95% CI 1.103–1.425, P < 0.001), but no association was found with minor ischemia after adjustment for age, sex, smoking, CVD family history, and physical activity level. Among MetS components, triglycerides, fasting blood glucose, waist circumference, and systolic and diastolic blood pressures were significantly associated with ischemic ECG presentations. Elevated high-density lipoprotein cholesterol level had a negative association with ischemic ECG presentations, while it had a significant positive association only with ST-segment elevation (OR = 1.021, 95% CI 1.011–1.031, P < 0.001).
Conclusions:
MetS and its components showed an association with ischemic ECG presentations, but these associations varied based on each MetS component and ischemic ECG abnormality.
Get full access to this article
View all access options for this article.
References
1.
MohamedSM, ShalabyMA, El-ShiekhRA, et al.Metabolic syndrome: Risk factors, diagnosis, pathogenesis, and management with natural approaches. Food Chemistry Advances, 2023; 3:100335.
2.
FahedG, AounL, Bou ZerdanM, et al.Metabolic syndrome: Updates on pathophysiology and management in 2021. Int J Mol Sci, 2022; 23(2):786.
3.
HanTS, LeanME. A clinical perspective of obesity, metabolic syndrome and cardiovascular disease. JRSM Cardiovasc Dis, 2016; 5:2048004016633371.
MooreKJ, ShahR. Introduction to the obesity, metabolic syndrome, and CVD compendium. Circ Res, 2020; 126(11):1475–1476.
6.
AkbariRadM, DarroudiS, FarsiF, et al.Investigation of the relationship between atherogenic index, anthropometric characteristics, and 10-year risk of metabolic syndrome: A population-based study. Ir J Med Sci, 2024; 193(6):2705–2711.
7.
O’NeillS, O’DriscollL. Metabolic syndrome: A closer look at the growing epidemic and its associated pathologies. Obes Rev, 2015; 16(1):1–12.
8.
HuhJH, KangDR, JangJ-Y, et al.Metabolic syndrome epidemic among Korean adults: Korean survey of Cardiometabolic Syndrome (2018). Atherosclerosis, 2018; 277:47–52.
9.
RanasingheP, MathangasingheY, JayawardenaR, et al.Prevalence and trends of metabolic syndrome among adults in the asia-pacific region: A systematic review. BMC Public Health, 2017; 17(1):101–109.
10.
FarmanfarmaKK, KaykhaeiMA, AdinehHA, et al.Prevalence of metabolic syndrome in Iran: A meta-analysis of 69 studies. Diabetes Metab Syndr, 2019; 13(1):792–799.
11.
RothGA, AbateD, AbateKH, et al.Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980–2017: A systematic analysis for the Global Burden of Disease Study 2017. The Lancet, 2018; 392(10159):1736–1788.
12.
GhalibafAM, SoflaeiSS, FernsGA, et al.Association between dietary copper and cardiovascular disease: A narrative review. J Trace Elem Med Biol, 2023; 80:127255.
13.
RothGA, MensahGA, JohnsonCO, et al.; GBD-NHLBI-JACC Global Burden of Cardiovascular Diseases Writing Group. Global burden of cardiovascular diseases and risk factors, 1990–2019: Update from the GBD 2019 study. J Am Coll Cardiol, 2020; 76(25):2982–3021.
14.
ZhaoD. Epidemiological features of cardiovascular disease in Asia. JACC Asia, 2021; 1(1):1–13.
15.
SahranavardT, SoflaeiSS, AlimiR, et al.Factors associated with prolonged QTc interval in Iranian population: MASHAD cohort study. J Electrocardiol, 2024; 84:112–122.
16.
HammadM, MaherA, WangK, et al.Detection of abnormal heart conditions based on characteristics of ECG signals. Measurement, 2018; 125:634–644.
17.
VijayavananM, RathikaraniV, DhanalakshmiP. Automatic classification of ECG signal for heart disease diagnosis using morphological features. Int J Computer Sci Engineering Technol, 2014; 5(4):449–455.
18.
Soflaei SaffarS, NazarE, SahranavardT, et al.Association of T-wave electrocardiogram changes and type 2 diabetes: A cross-sectional sub-analysis of the MASHAD cohort population using the Minnesota coding system. BMC Cardiovasc Disord, 2024; 24(1):48.
19.
NawazB, FrommA, ØygardenH, et al.Prevalence of atherosclerosis and association with 5-year outcome: The Norwegian Stroke in the Young Study. Eur Stroke J, 2021; 6(4):374–384.
20.
LeeSH, LeeMY, KangJ, et al.Association between ECG abnormalities and mortality in a low‐risk population. J Am Heart Assoc, 2024; 13(5):e033306.
21.
NiuJ, DengC, ZhengR, et al.The association and predictive ability of ECG abnormalities with cardiovascular diseases: A prospective analysis. Glob Heart, 2020; 15(1):59.
22.
Saffar SoflaeiS, EbrahimiM, RahimiHR, et al.A large population‐based study on the prevalence of electrocardiographic abnormalities: A result of Mashhad stroke and heart atherosclerotic disorder cohort study. Ann Noninvasive Electrocardiol, 2023; 28(6):e13086.
23.
ArnlövJ, IngelssonE, SundströmJ, et al.Impact of body mass index and the metabolic syndrome on the risk of cardiovascular disease and death in middle-aged men. Circulation, 2010; 121(2):230–236.
NicolaouVN, PapadakisJE, KaratzisEN, et al.Impact of the metabolic syndrome on atrial size in patients with new-onset atrial fibrillation. Angiology, 2007; 58(1):21–25.
26.
Silveira RossiJL, BarbalhoSM, Reverete de AraujoR, et al.Metabolic syndrome and cardiovascular diseases: Going beyond traditional risk factors. Diabetes Metab Res Rev, 2022; 38(3):e3502.
27.
Chee CheongK, LimKH, GhazaliSM, et al.Association of metabolic syndrome with risk of cardiovascular disease mortality and all-cause mortality among Malaysian adults: A retrospective cohort study. BMJ Open, 2021; 11(8):e047849.
28.
GuembeMJ, Fernandez-LazaroCI, Sayon-OreaC, et al.; RIVANA Study Investigators. Risk for cardiovascular disease associated with metabolic syndrome and its components: A 13-year prospective study in the RIVANA cohort. Cardiovasc Diabetol, 2020; 19(1):195.
29.
AzadnajafabadS, MohammadiE, AminorroayaA, et al.Non-communicable diseases’ risk factors in Iran; a review of the present status and action plans. J Diabetes Metab Disord, 2021; 23(2):1–9.
30.
AhmadiA, ShiraniM, KhaledifarA, et al.Non-communicable diseases in the southwest of Iran: Profile and baseline data from the Shahrekord PERSIAN Cohort Study. BMC Public Health, 2021; 21(1):2275.
31.
NikbakhtH-A, RezaianzadehA, SeifM, et al.Prevalence of metabolic syndrome and its components among a population-based study in south of Iran, PERSIAN Kharameh cohort study. Clin Epidemiology Global Health, 2020; 8(3):678–683.
32.
Ghayour-MobarhanM, MoohebatiM, EsmailyH, et al.Mashhad stroke and heart atherosclerotic disorder (MASHAD) study: Design, baseline characteristics and 10-year cardiovascular risk estimation. Int J Public Health, 2015; 60(5):561–572.
33.
NortonK, WhittinghamN, CarterL, et al.Measurement Techniques in Anthropometry. Eds: Kevin Norton & Tim Olds, Anthropometrica, Australia. Unsw Press; 1996.
34.
MuntnerP, ShimboD, CareyRM, et al.Measurement of blood pressure in humans: A scientific statement from the American Heart Association. Hypertension, 2019; 73(5):e35–e66.
35.
AlbertiK, ZimmetP, ShawJ. A consensus statement from the international diabetes federation. Diabet Med, 2006; 23(469):80.
36.
PrineasRJ, CrowRS, ZhangZ-M. The Minnesota Code Manual of Electrocardiographic Findings: Springer Science & Business Media; 2009.
37.
KimH-K, KimC-H, KoK-H, et al.Variable association between components of the metabolic syndrome and electrocardiographic abnormalities in Korean adults. Korean J Intern Med, 2010; 25(2):174–180.
38.
NabipourI, AmiriM, ImamiSR, et al.The metabolic syndrome and nonfatal ischemic heart disease; a population-based study. Int J Cardiol, 2007; 118(1):48–53.
39.
EbongIA, BertoniAG, SolimanEZ, et al.Electrocardiographic abnormalities associated with the metabolic syndrome and its components: The multi-ethnic study of atherosclerosis. Metab Syndr Relat Disord, 2012; 10(2):92–97.
40.
CleemanJ, GrundyS, BeckerD, et al.Expert panel on detection, evaluation and treatment of high blood cholesterol in adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Adult Treatment Panel (ATP III). JAMA, 2001; 285(19):2486–2497.
41.
MillerM, StoneNJ, BallantyneC, et al.; Council on the Kidney in Cardiovascular Disease. Triglycerides and cardiovascular disease: A scientific statement from the American Heart Association. Circulation, 2011; 123(20):2292–2333.
42.
ChaitA, GinsbergHN, VaisarT, et al.Remnants of the triglyceride-rich lipoproteins, diabetes, and cardiovascular disease. Diabetes, 2020; 69(4):508–516.
43.
MoshkovitsY, RottD, ChetritA, et al.The association between insulin sensitivity indices, ECG findings and mortality: A 40-year cohort study. Cardiovasc Diabetol, 2021; 20(1):97.
44.
SumnerAE. Ethnic differences in triglyceride levels and high-density lipoprotein lead to underdiagnosis of the metabolic syndrome in black children and adults. The Journal of Pediatrics, 2009; 155(3):S7. e7-S7–Se11.
45.
GodslandIF, JohnstonDG, ChaturvediN. Mechanisms of disease: Lessons from ethnicity in the role of triglyceride metabolism in ischemic heart disease. Nat Clin Pract Endocrinol Metab, 2007; 3(7):530–538.
46.
FaramawiMF, SallM, KareemMYA. The association of the metabolic syndrome with T-wave axis deviation in NHANES III. Annals of Epidemiology, 2008; 18(9):702–707.
47.
KumarA, PrineasRJ, ArnoldAM, et al.Prevalence, prognosis, and implications of isolated minor nonspecific ST-segment and T-wave abnormalities in older adults: Cardiovascular Health Study. Circulation, 2008; 118(25):2790–2796.
48.
YazdanpanahMH, SayyadipoorS, HojatiSR, et al.The association of metabolic syndrome and its components with electrocardiogram parameters and abnormalities among an Iranian rural population: The Fasa PERSIAN Cohort Study. Diabetes Metab Syndr Obes, 2020; 13:2975–2987.
49.
MurphyBP, StantonT, DunnFG. Hypertension and myocardial ischemia. Med Clin North Am, 2009; 93(3):681–695.
50.
RodrigoR, LibuyM, FeliúF, et al.Oxidative stress-related biomarkers in essential hypertension and ischemia-reperfusion myocardial damage. Dis Markers, 2013; 35(6):773–790.
51.
BarrosoTA, MarinsLB, AlvesR, et al.Association of central obesity with the incidence of cardiovascular diseases and risk factors. Int J Cardiovascular Sciences, 2017; 30:416–424.
52.
ShirasawaT, OchiaiH, YoshimotoT, et al.Associations between normal weight central obesity and cardiovascular disease risk factors in Japanese middle-aged adults: A cross-sectional study. J Health Popul Nutr, 2019; 38(1):1–7.
53.
RitchieS, ConnellJ. The link between abdominal obesity, metabolic syndrome and cardiovascular disease. Nutr Metab Cardiovasc Dis, 2007; 17(4):319–326.
54.
AhnN, KimK. High-density lipoprotein cholesterol (HDL-C) in cardiovascular disease: Effect of exercise training. Integr Med Res, 2016; 5(3):212–215.
55.
RaderDJ, HovinghGK. HDL and cardiovascular disease. Lancet, 2014; 384(9943):618–625.
56.
OzT, ÖzbilginN, SungurA, et al.Prevalence of metabolic syndrome in young patients with ST-elevation myocardial infarction. Int J Cardiovasc Acad, 2018; 4(3):53.
57.
Fabregat-AndrésÓ, Ferrando-BeltránM, Lucas-InarejosE, et al.High-density lipoproteins and myocardial necrosis in patients with acute myocardial infarction and ST segment elevation. Revista Clínica Española (English Edition), 2013; 213(2):75–80.
58.
MabryR, ReevesM, EakinE, et al.Gender differences in prevalence of the metabolic syndrome in Gulf Cooperation Council Countries: A systematic review. Diabet Med, 2010; 27(5):593–597.
59.
BeighSH, JainS. Prevalence of metabolic syndrome and gender differences. Bioinformation, 2012; 8(13):613–616.
60.
XuS-H, QiaoN, HuangJ-J, et al.Gender differences in dietary patterns and their association with the prevalence of metabolic syndrome among Chinese: A cross-sectional study. Nutrients, 2016; 8(4):180.
61.
ParkE, KimJ. Gender-and age-specific prevalence of metabolic syndrome among Korean adults: Analysis of the fifth Korean National Health and Nutrition Examination Survey. J Cardiovasc Nurs, 2015; 30(3):256–266.
62.
HirodeG, WongRJ. Trends in the prevalence of metabolic syndrome in the United States, 2011-2016. JAMA, 2020; 323(24):2526–2528.
63.
PucciG, AlcidiR, TapL, et al.Sex-and gender-related prevalence, cardiovascular risk and therapeutic approach in metabolic syndrome: A review of the literature. Pharmacol Res, 2017; 120:34–42.
64.
LeeS, KoY, KwakC, et al.Gender differences in metabolic syndrome components among the Korean 66-year-old population with metabolic syndrome. BMC Geriatr, 2016; 16:27–28.
65.
YangJJ, YoonH-S, LeeS-A, et al.Metabolic syndrome and sex‐specific socio‐economic disparities in childhood and adulthood: The Korea National Health and Nutrition Examination Surveys. Diabet Med, 2014; 31(11):1399–1409.
